Liquidia Corporation

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

lqda

Other Non-Current Liabilities

Last Annual Value

4.75M

3-Year CAGR

-10%

5-Year CAGR

33%

10-Year CAGR

26%

Liquidia Corporation

Liquidia Corporation Competitors Analysis of Other Non-Current Liabilities

LQDA · NASDAQ
CompanyOther Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.75M
-10.9%-5.0%26.4% 
-14.32M
N/AN/AN/A
647.00K
29.5%-67.1%N/A
0.00
N/AN/AN/A
ETNB logo
89bio, Inc.
NASDAQ:ETNB
4.95M
9.8%177.6%N/A
70.89M
-38.9%209.7%38.8%
178.00M
7.8%102.2%43.8%
11.97M
-26.4%-9.9%36.4%
-21.73M
N/AN/AN/A
Liquidia Corporation

Liquidia Corporation Fair Value Envelope

LQDA · NASDAQ

Our analysis suggests that LQDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $55.69, this represents a potential HIDDEN relative to our calculated worth for Liquidia Corporation.

Intrinsic Value
Current Price: $55.69